Adverum Biotechnologies (ADVM) Getting Somewhat Favorable Press Coverage, Analysis Shows

Headlines about Adverum Biotechnologies (NASDAQ:ADVM) have trended somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Adverum Biotechnologies earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 44.9314365022537 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Adverum Biotechnologies (NASDAQ ADVM) traded up $0.30 on Thursday, reaching $4.65. The company’s stock had a trading volume of 660,100 shares, compared to its average volume of 1,122,955. The company has a market cap of $209.44, a price-to-earnings ratio of -3.10 and a beta of 2.44. Adverum Biotechnologies has a fifty-two week low of $2.40 and a fifty-two week high of $4.65.

Adverum Biotechnologies (NASDAQ:ADVM) last released its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.03). The business had revenue of $0.46 million for the quarter. Adverum Biotechnologies had a negative net margin of 3,398.29% and a negative return on equity of 26.60%. research analysts expect that Adverum Biotechnologies will post -1.31 EPS for the current year.

A number of equities research analysts have recently weighed in on ADVM shares. Zacks Investment Research raised Adverum Biotechnologies from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Chardan Capital reaffirmed a “hold” rating on shares of Adverum Biotechnologies in a research report on Tuesday, December 19th. ValuEngine lowered Adverum Biotechnologies from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 9th. Finally, Raymond James Financial started coverage on Adverum Biotechnologies in a research report on Thursday, October 12th. They set an “outperform” rating and a $6.00 price target for the company.

COPYRIGHT VIOLATION WARNING: “Adverum Biotechnologies (ADVM) Getting Somewhat Favorable Press Coverage, Analysis Shows” was reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.truebluetribune.com/2018/01/18/adverum-biotechnologies-advm-getting-somewhat-favorable-press-coverage-analysis-shows.html.

About Adverum Biotechnologies

Adverum Biotechnologies, Inc, formerly Avalanche Biotechnologies, Inc, is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics.

Insider Buying and Selling by Quarter for Adverum Biotechnologies (NASDAQ:ADVM)

Receive News & Ratings for Adverum Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply